Skip to content
Cenicriviroc
Cenicriviroc is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target C-C chemokine receptor type 5.
Download report
Favorite
COVID-19
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.81—41——5
Covid-19D000086382U07.1—21——3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B2013———3
Liver cirrhosisD008103EFO_0001422K74.0—1———1
Sclerosing cholangitisD015209EFO_0004268K83.01—1———1
Type 2 diabetes mellitusD003924EFO_0001360E11—1———1
Prediabetic stateD011236EFO_1001121R73.03—1———1
HivD006678O98.7—1———1
Aids dementia complexD015526EFO_0002608—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatic insufficiencyD0485502————2
Healthy volunteers/patients—2————2
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCENICRIVIROC
INNcenicriviroc
Description
Cenicriviroc is a member of the class of benzazocines that is (5Z)-1,2,3,4-tetrahydro-1-benzazocine which is substituted by a 2-methylpropyl, N-{4-[(S)-(1-propyl-1H-imidazol-5-yl)methanesulfinyl]phenyl}carboxamide and 4-(2-butoxyethoxy)phenyl groups at positions 1, 5 and 8, respectively. It is a potent chemokine 2 and 5 receptor antagonist currently in development for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis (NASH). It has a role as a chemokine receptor 5 antagonist, an anti-HIV agent, a chemokine receptor 2 antagonist, an antirheumatic drug and an anti-inflammatory agent. It is a diether, a member of imidazoles, a sulfoxide, an aromatic ether, a secondary carboxamide and a benzazocine.
Classification
Small molecule
Drug classantivirals; antivirals, chemokine receptor (CCR) antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCOCCOc1ccc(-c2ccc3c(c2)/C=C(/C(=O)Nc2ccc([S@@+]([O-])Cc4cncn4CCC)cc2)CCCN3CC(C)C)cc1
Identifiers
PDB—
CAS-ID497223-25-3
RxCUI—
ChEMBL IDCHEMBL2110727
ChEBI ID—
PubChem CID11285792
DrugBankDB11758
UNII ID15C116UA4Y (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CCR5
CCR5
Organism
Homo sapiens
Gene name
CCR5
Gene synonyms
CMKBR5
NCBI Gene ID
1234
Protein name
C-C chemokine receptor type 5
Protein synonyms
C-C motif chemokine receptor 5 A159A, CD195, chemokine (C-C motif) receptor 5, chemokine receptor CCR5, chemokine recptor CCR5 Delta32, CHEMR13, HIV-1 fusion coreceptor, mutant C-C motif chemokine receptor
Uniprot ID
Q9UPA4
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 849 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,192 adverse events reported
View more details